Guest Editors
Professor William Russell Miller
Email: w.r.miller@ed.ac.uk
Affiliation: Emeritus Professor, Faculty of Medicine University of Edinburgh, Edinburgh, EH16 4SB, UK
Homepage:
Research Interests: breast Cancer, translation research, hormones
Professor J Michael Dixon
Email: Mike.Dixon@ed.ac.uk
Affiliation: Edinburgh Breast Unit, Western General Hospital, EH4 2XU, Edinburgh, UK
Homepage:
Research Interests: Breast Cancer, Surgery
Summary
The theme of the Controversies in Breast Cancer meetings, held in 2007, 2008, and 2009, and published as peer-reviewed communications, was to systematically dissect the underlying reasons for unresolved issues. Now, over 15 years on, the original authors will update their perspectives as to how their controversial topic has evolved over the intervening years, what has progressed, and what has not, and why.
The specific controversies to be considered are:
Personalized Treatment
Short-term neoadjuvant treatment
Adjuvant treatment:
Prognostic markers and expression micro arrays
Endocrine Therapy
Pharmacokinetics, pharmacodynamics, and pharmacogenomics
Markers of endocrine sensitivity
Mechanisms of response and resistance
Integration with other therapies
Optimization of Therapy
Tailored targeted therapy
Paradigms for Future Research
Circulating tumour cells and other biomarkers of systemic disease
mRNA-based genomic predictors
Tumour DNA by new generation sequencing
Are Current Drug Development Programmes Realizing the Full Potential of Drugs
The scenario
Pre-clinical models
Tyrosine kinase inhibitors
Perspective of the pharmaceutical industry
Keywords
breast cancer, controversies, oncology research
Login
Register
Submit a Paper
Propose a Special lssue